Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
grade F 11.01 -1.43% -0.16
CORT closed down 1.43 percent on Monday, March 25, 2019, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CORT trend table...

Date Alert Name Type % Chg
Mar 25 NR7 Range Contraction 0.00%
Mar 25 Below Lower BB Weakness 0.00%
Mar 25 Down 3 Days in a Row Weakness 0.00%
Mar 25 Down 4 Days in a Row Weakness 0.00%
Mar 25 Down 5 Days in a Row Weakness 0.00%
Mar 25 Oversold Stochastic Weakness 0.00%
Mar 22 Below Lower BB Weakness -1.43%
Mar 22 Down 3 Days in a Row Weakness -1.43%
Mar 22 Down 4 Days in a Row Weakness -1.43%
Mar 22 Lower Bollinger Band Touch Weakness -1.43%

Older signals for CORT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Pharmaceutical Surgery Organ Systems Disorders Endocrine System Hormones Diabetes Mellitus Depression Cushing's Syndrome Corcept Therapeutics Hyperglycemia Cortisol Endogenous Cushing's Syndrome
Is CORT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.0
52 Week Low 9.14
Average Volume 1,708,816
200-Day Moving Average 13.5935
50-Day Moving Average 12.3164
20-Day Moving Average 12.1825
10-Day Moving Average 11.988
Average True Range 0.518
ADX 14.74
+DI 15.5327
-DI 30.2352
Chandelier Exit (Long, 3 ATRs ) 11.476
Chandelier Exit (Short, 3 ATRs ) 12.494
Upper Bollinger Band 13.0778
Lower Bollinger Band 11.2872
Percent B (%b) -0.15
BandWidth 14.698133
MACD Line -0.1717
MACD Signal Line -0.0511
MACD Histogram -0.1206
Fundamentals Value
Market Cap 1.25 Billion
Num Shares 113 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 55.05
Price-to-Sales 19.04
Price-to-Book 31.30
PEG Ratio 0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.46
Resistance 3 (R3) 11.49 11.36 11.39
Resistance 2 (R2) 11.36 11.25 11.35 11.36
Resistance 1 (R1) 11.19 11.18 11.13 11.16 11.33
Pivot Point 11.06 11.06 11.03 11.05 11.06
Support 1 (S1) 10.89 10.95 10.83 10.86 10.69
Support 2 (S2) 10.76 10.88 10.75 10.66
Support 3 (S3) 10.59 10.76 10.64
Support 4 (S4) 10.56